Cargando…
The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139949/ https://www.ncbi.nlm.nih.gov/pubmed/32120855 http://dx.doi.org/10.3390/cancers12030551 |
_version_ | 1783518883983917056 |
---|---|
author | Fang, Wen-Liang Chen, Ming-Huang Huang, Kuo-Hung Chang, Shih-Ching Lin, Chien-Hsing Chao, Yee Lo, Su-Shun Li, Anna Fen-Yau Wu, Chew-Wun Shyr, Yi-Ming |
author_facet | Fang, Wen-Liang Chen, Ming-Huang Huang, Kuo-Hung Chang, Shih-Ching Lin, Chien-Hsing Chao, Yee Lo, Su-Shun Li, Anna Fen-Yau Wu, Chew-Wun Shyr, Yi-Ming |
author_sort | Fang, Wen-Liang |
collection | PubMed |
description | Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status, mutations of common GC-related genes and 16 DNA repair-associated genes, and the clinicopathological features were analyzed. Results: Among the 360 GC patients enrolled, there were 76 (21.1%) with EMAST+ tumors and 284 with EMAST− tumors, and 59 (16.4%) were MSI-high (MSI-H) tumors, and 301 were microsatellite stable (MSS) tumors. Patients with EMAST+ tumors exhibited an earlier pathological T category and had more genetic mutations in the PI3K/AKT pathway, ARID1A and DNA repair-associated genes than those with EMAST− tumors. Patients with MSI-H tumors have more genetic mutations in the PI3K/AKT pathway and DNA repair-associated genes than those with MSS tumors. In the subgroup analysis for MSI-H GC, EMAST+ tumors were associated with earlier pathological T and N categories, earlier TNM stages, higher frequency of DNA-repair-associated genetic mutations, and a better survival rate than EMAST− tumors. Conclusions: PI3K/AKT pathway mutations may play an important role in EMAST+ and/or MSI-H GC. EMAST+/MSI-H tumors seem to represent a different subtype of gastric cancer from EMAST−/MSI-H tumors. |
format | Online Article Text |
id | pubmed-7139949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71399492020-04-13 The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status Fang, Wen-Liang Chen, Ming-Huang Huang, Kuo-Hung Chang, Shih-Ching Lin, Chien-Hsing Chao, Yee Lo, Su-Shun Li, Anna Fen-Yau Wu, Chew-Wun Shyr, Yi-Ming Cancers (Basel) Article Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status, mutations of common GC-related genes and 16 DNA repair-associated genes, and the clinicopathological features were analyzed. Results: Among the 360 GC patients enrolled, there were 76 (21.1%) with EMAST+ tumors and 284 with EMAST− tumors, and 59 (16.4%) were MSI-high (MSI-H) tumors, and 301 were microsatellite stable (MSS) tumors. Patients with EMAST+ tumors exhibited an earlier pathological T category and had more genetic mutations in the PI3K/AKT pathway, ARID1A and DNA repair-associated genes than those with EMAST− tumors. Patients with MSI-H tumors have more genetic mutations in the PI3K/AKT pathway and DNA repair-associated genes than those with MSS tumors. In the subgroup analysis for MSI-H GC, EMAST+ tumors were associated with earlier pathological T and N categories, earlier TNM stages, higher frequency of DNA-repair-associated genetic mutations, and a better survival rate than EMAST− tumors. Conclusions: PI3K/AKT pathway mutations may play an important role in EMAST+ and/or MSI-H GC. EMAST+/MSI-H tumors seem to represent a different subtype of gastric cancer from EMAST−/MSI-H tumors. MDPI 2020-02-27 /pmc/articles/PMC7139949/ /pubmed/32120855 http://dx.doi.org/10.3390/cancers12030551 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fang, Wen-Liang Chen, Ming-Huang Huang, Kuo-Hung Chang, Shih-Ching Lin, Chien-Hsing Chao, Yee Lo, Su-Shun Li, Anna Fen-Yau Wu, Chew-Wun Shyr, Yi-Ming The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status |
title | The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status |
title_full | The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status |
title_fullStr | The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status |
title_full_unstemmed | The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status |
title_short | The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status |
title_sort | clinicopathological features and genetic mutations in gastric cancer patients according to emast and msi status |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139949/ https://www.ncbi.nlm.nih.gov/pubmed/32120855 http://dx.doi.org/10.3390/cancers12030551 |
work_keys_str_mv | AT fangwenliang theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT chenminghuang theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT huangkuohung theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT changshihching theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT linchienhsing theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT chaoyee theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT losushun theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT liannafenyau theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT wuchewwun theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT shyryiming theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT fangwenliang clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT chenminghuang clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT huangkuohung clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT changshihching clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT linchienhsing clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT chaoyee clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT losushun clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT liannafenyau clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT wuchewwun clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus AT shyryiming clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus |